These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 11096218)

  • 41. Change in PASAT performance correlates with change in P3 ERP amplitude over a 12-month period in multiple sclerosis patients.
    Kiiski H; Reilly RB; Lonergan R; Kelly S; O'Brien M; Kinsella K; Bramham J; Burke T; O'Donnchadha S; Nolan H; Hutchinson M; Tubridy N; Whelan R
    J Neurol Sci; 2011 Jun; 305(1-2):45-52. PubMed ID: 21457995
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Interferon-beta1b in multiple sclerosis.
    Buttmann M; Rieckmann P
    Expert Rev Neurother; 2007 Mar; 7(3):227-39. PubMed ID: 17341170
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Time-course analysis of CD25 and HLA-DR expression on lymphocytes in interferon-beta 1b-treated multiple sclerosis patients.
    Ferrarini AM; Sivieri S; Buttarello M; Facchinetti A; Perini P; Gallo P
    Mult Scler; 1998 Jun; 4(3):174-7. PubMed ID: 9762669
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of interferon beta-1a on optic neuritis relapse in patients with multiple sclerosis.
    Chen YM; Yang CC; Wang IH; Hu FR; Jou JR
    Graefes Arch Clin Exp Ophthalmol; 2010 Feb; 248(2):231-5. PubMed ID: 19806357
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Severe liver dysfunction possibly caused by the combination of interferon beta-1b therapy and melilot (sweet clover) supplement.
    Tamura S; Warabi Y; Matsubara S
    J Clin Pharm Ther; 2012 Dec; 37(6):724-5. PubMed ID: 22642738
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Differing immunogenic potentials of interferon beta preparations in multiple sclerosis patients.
    Gneiss C; Tripp P; Reichartseder F; Egg R; Ehling R; Lutterotti A; Khalil M; Kuenz B; Mayringer I; Reindl M; Berger T; Deisenhammer F
    Mult Scler; 2006 Dec; 12(6):731-7. PubMed ID: 17263000
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Cognitive disturbances and attempts of their correction in multiple sclerosis].
    Shmidt TE
    Zh Nevrol Psikhiatr Im S S Korsakova; 2005; 105(9):54-6. PubMed ID: 16252387
    [No Abstract]   [Full Text] [Related]  

  • 48. The role of event-related potentials in cognitive decline in Alzheimer's disease.
    Lai CL; Lin RT; Liou LM; Liu CK
    Clin Neurophysiol; 2010 Feb; 121(2):194-9. PubMed ID: 20005164
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Interferon beta-1a and beta-1b for treatment of multiple sclerosis.
    Benatar M
    Lancet; 2002 Nov; 360(9343):1428; author reply 1428-9. PubMed ID: 12424021
    [No Abstract]   [Full Text] [Related]  

  • 50. Liver and thyroid function and autoimmunity during interferon-beta 1b treatment for MS.
    Durelli L; Ferrero B; Oggero A; Verdun E; Ghezzi A; Montanari E; Zaffaroni M;
    Neurology; 2001 Oct; 57(8):1363-70. PubMed ID: 11673572
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cost-effectiveness of interferon beta-1a, interferon beta-1b, and glatiramer acetate in newly diagnosed non-primary progressive multiple sclerosis.
    Prosser LA; Kuntz KM; Bar-Or A; Weinstein MC
    Value Health; 2004; 7(5):554-68. PubMed ID: 15367251
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Severe local skin reactions to interferon beta-1b in multiple sclerosis-improvement by deep subcutaneous injection.
    Nakamura Y; Kawachi Y; Furuta J; Otsuka F
    Eur J Dermatol; 2008; 18(5):579-82. PubMed ID: 18693165
    [TBL] [Abstract][Full Text] [Related]  

  • 53. The effect of interferon beta 1B on bone mineral density in multiple sclerosis patients.
    Varoglu AO; Varoglu E; Bayraktar R; Aygul R; Ulvi H; Yildirim K
    J Back Musculoskelet Rehabil; 2010; 23(1):25-9. PubMed ID: 20231786
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Evaluating sub-clinical cognitive dysfunction and event-related potentials (P300) in clinically isolated syndrome.
    Kocer B; Unal T; Nazliel B; Biyikli Z; Yesilbudak Z; Karakas S; Irkec C
    Neurol Sci; 2008 Dec; 29(6):435-44. PubMed ID: 19002651
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Interferon, azathioprine and corticosteroids in multiple sclerosis: 6-year follow-up of the ASA cohort.
    Kalincik T; Horakova D; Dolezal O; Krasensky J; Vaneckova M; Seidl Z; Havrdova E
    Clin Neurol Neurosurg; 2012 Sep; 114(7):940-6. PubMed ID: 22402204
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGnitive Impairment in MUltiple Sclerosis) study.
    Patti F; Amato MP; Trojano M; Bastianello S; Tola MR; Picconi O; Cilia S; Cottone S; Centonze D; Gasperini C;
    Mult Scler; 2011 Aug; 17(8):991-1001. PubMed ID: 21502310
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?
    Verdun E; Isoardo G; Oggero A; Ferrero B; Ghezzi A; Montanari E; Zaffaroni M; Durelli L;
    J Interferon Cytokine Res; 2002 Feb; 22(2):245-55. PubMed ID: 11911808
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Contribution of cognitive evoked potentials for detecting early cognitive disorders in multiple sclerosis].
    Magnié MN; Bensa C; Laloux L; Bertogliati C; Faure S; Lebrun C
    Rev Neurol (Paris); 2007 Nov; 163(11):1065-74. PubMed ID: 18033045
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A study of cognitive fatigue in Multiple Sclerosis with novel clinical and electrophysiological parameters utilizing the event related potential P300.
    Chinnadurai SA; Venkatesan SA; Shankar G; Samivel B; Ranganathan LN
    Mult Scler Relat Disord; 2016 Nov; 10():1-6. PubMed ID: 27919474
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [The use of beta-interferon-1b in children and adolescents with multiple sclerosis].
    Bykova OV; Kuzenkova LM; Maslova OI
    Zh Nevrol Psikhiatr Im S S Korsakova; 2006; 106(9):29-33. PubMed ID: 17069059
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.